Počet záznamů: 1
Trifluoromethylcinnamanilide Michael Acceptors for Treatment of Resistant Bacterial Infections
- 1.
SYSNO ASEP 0566362 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Trifluoromethylcinnamanilide Michael Acceptors for Treatment of Resistant Bacterial Infections Tvůrce(i) Strharsky, T. (CZ)
Pindjakova, D. (SK)
Kos, J. (SK)
Vrablova, L. (SK)
Smak, P. (CZ)
Michnová, H. (CZ)
Gonec, T. (CZ)
Hošek, J. (CZ)
Oravec, Michal (UEK-B) RID, ORCID, SAI
Jendrzejewska, I. (PL)
Čížek, A. (CZ)
Jampílek, J. (SK)Celkový počet autorů 12 Číslo článku 15090 Zdroj.dok. International Journal of Molecular Sciences. - : MDPI
Roč. 23, č. 23 (2022)Poč.str. 22 s. Jazyk dok. eng - angličtina Země vyd. CH - Švýcarsko Klíč. slova cinnamamides ; Michael acceptors ; antimicrobial activity ; cytotoxicity ; lipophilicity ; structure-activity relationships ; docking study Vědní obor RIV CE - Biochemie Obor OECD Biochemistry and molecular biology CEP LM2018123 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy EF16_019/0000797 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy Způsob publikování Open access Institucionální podpora UEK-B - RVO:86652079 UT WOS 000897240400001 EID SCOPUS 85143746002 DOI 10.3390/ijms232315090 Anotace A series of thirty-two anilides of 3-(trifluoromethyl)cinnamic acid (series 1) and 4-(trifluoromethyl)cinnamic acid (series 2) was prepared by microwave-assisted synthesis. All the compounds were tested against reference strains Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 and resistant clinical isolates of methicillin-resistant S. aureus (MRSA) and vancomycin-resistant E. faecalis (VRE). All the compounds were evaluated in vitro against Mycobacterium smegmatis ATCC 700084 and M. marinum CAMP 5644. (2E)-3-[3-(Trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]prop-2-enamide (1j), (2E)-N-(3,5-dichlorophenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-enamide (1o) and (2E)-N-[3-(trifluoromethyl)phenyl]-3-[4-(trifluoromethyl)-phenyl]prop-2-enamide (2i), (2E)-N-[3,5-bis(trifluoromethyl)phenyl]-3-[4-(trifluoromethyl)phenyl]-prop-2-enamide (2p) showed antistaphylococcal (MICs/MBCs 0.15-5.57 mu M) as well as anti-enterococcal (MICs/MBCs 2.34-44.5 mu M) activity. The growth of M. marinum was strongly inhibited by compounds 1j and 2p in a MIC range from 0.29 to 2.34 mu M, while all the agents of series 1 showed activity against M. smegnatis (MICs ranged from 9.36 to 51.7 mu M). The performed docking study demonstrated the ability of the compounds to bind to the active site of the mycobacterial enzyme InhA. The compounds had a significant effect on the inhibition of bacterial respiration, as demonstrated by the MTT assay. The compounds showed not only bacteriostatic activity but also bactericidal activity. Preliminary in vitro cytotoxicity screening was assessed using the human monocytic leukemia cell line THP-1 and, except for compound 2p, all effective agents did show insignificant cytotoxic effect. Compound 2p is an interesting anti-invasive agent with dual (cytotoxic and antibacterial) activity, while compounds 1j and 1o are the most interesting purely antibacterial compounds within the prepared molecules. Pracoviště Ústav výzkumu globální změny Kontakt Nikola Šviková, svikova.n@czechglobe.cz, Tel.: 511 192 268 Rok sběru 2023 Elektronická adresa https://www.mdpi.com/1422-0067/23/23/15090
Počet záznamů: 1